{"product_id":"tesamorelin","title":"Tesamorelin","description":"\u003ch2\u003eAbout Tesamorelin\u003c\/h2\u003e\n\u003cp\u003eTesamorelin is a synthetic 44 residue analogue of human growth hormone releasing hormone, distinguished from the native peptide by a trans 3 hexenoyl group at the amino terminus. Peptsche offers it as a lyophilized powder in a sealed vial, prepared by solid phase synthesis and characterised by chromatography and mass spectrometry. Because the same molecule is also the active ingredient of an approved prescription medicine, the distinction between that product and this laboratory reagent is set out plainly below. Peptsche supplies Tesamorelin strictly as a research material for controlled laboratory investigation.\u003c\/p\u003e\n\n\u003ch3\u003eAvailable Sizes\u003c\/h3\u003e\n\u003cp\u003eOffered in one vial configuration, sealed with a butyl closure and crimp.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e10 mg lyophilized Tesamorelin per vial\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eProduct Specifications\u003c\/h3\u003e\n\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTesamorelin, research grade lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIn vitro and laboratory research use only. Not for human or veterinary use.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAppearance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWhite to off white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eChemical Formula\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eC\u003csub\u003e221\u003c\/sub\u003eH\u003csub\u003e366\u003c\/sub\u003eN\u003csub\u003e72\u003c\/sub\u003eO\u003csub\u003e67\u003c\/sub\u003eS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e5135.9 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCAS Number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e218949-48-5 (acetate salt 804475-66-9)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePubChem CID\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/16137828\" target=\"_blank\" rel=\"noopener\"\u003e16137828\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eA 44 residue growth hormone releasing hormone analogue, N terminally acylated with trans 3 hexenoyl. One letter code YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL with a C terminal amide.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTH9507, hexenoyl somatoliberin, GHRH(1-44) analogue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e99% or greater by HPLC, verified per batch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStore sealed at 2 to 8 °C, protected from heat, light and moisture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThe tesamorelin molecule is the active ingredient in an approved prescription medicine marketed as Egrifta by Theratechnologies, approved by the United States Food and Drug Administration in 2010. The material supplied by Peptsche is a research grade compound. It is not that approved medicine, is not manufactured to pharmaceutical standards, and is not approved for human or veterinary use.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\n\u003ch2\u003eWhat is Tesamorelin?\u003c\/h2\u003e\n\u003cp\u003eGrowth hormone releasing hormone, also called somatoliberin, is a 44 residue hypothalamic peptide acting on somatotroph cells of the anterior pituitary. Tesamorelin retains the complete sequence rather than the truncated fragment used in many analogues, and adds a six carbon unsaturated acyl group at the amino terminus.\u003c\/p\u003e\n\u003cp\u003eThat acyl modification is the defining chemical feature. It sits at the position most vulnerable to aminopeptidase attack and alters the conformation of the amino terminus, the region responsible for activation. The result is a ligand that keeps agonist character while resisting the rapid trimming that limits the native hormone as a laboratory tool.\u003c\/p\u003e\n\u003cp\u003eThe regulatory distinction should stay clear. The same molecule is manufactured under pharmaceutical controls by its developer and sold as an approved prescription product. The material offered here is a research reagent. It shares the chemical structure but not the manufacturing controls, formulation, excipients or regulatory status of that medicine, and clinical data on the medicine does not characterise this reagent.\u003c\/p\u003e\n\n\u003ch2\u003eTesamorelin Mechanism of Action (Research Only)\u003c\/h2\u003e\n\u003cp\u003eMechanistic interest centres on one receptor system and on how the acyl modification and chain length alter ligand behaviour.\u003c\/p\u003e\n\n\u003ch3\u003eGrowth Hormone Releasing Hormone Receptor Agonism\u003c\/h3\u003e\n\u003cp\u003eTesamorelin binds the growth hormone releasing hormone receptor on anterior pituitary somatotrophs. That class B G protein coupled receptor signals mainly through the stimulatory G protein, raising cyclic adenosine monophosphate and activating protein kinase A. Standard cell based readouts are cyclic nucleotide accumulation and secretory output from pituitary cultures, with the amino terminal region serving as the activating element.\u003c\/p\u003e\n\n\u003ch3\u003eThe Hexenoyl Modification and Stability\u003c\/h3\u003e\n\u003cp\u003eThe trans 3 hexenoyl group shields the first residues from aminopeptidase and dipeptidyl peptidase activity, the pathways that clear the native hormone quickly from serum. The hydrophobic acyl chain also influences aggregation and solubility, which matters when preparing reference solutions. The practical consequence is a longer usable measurement window in matrices where the unmodified hormone would already have degraded.\u003c\/p\u003e\n\n\u003ch3\u003eFull Length 44 Residue Structure\u003c\/h3\u003e\n\u003cp\u003eMost analogues in this family are built on the first 29 residues, the minimal fragment retaining receptor activity. Tesamorelin instead carries the complete 44 residue chain with a carboxyl terminal amide. That extra region adds helical stability and binding surface, making the molecule a useful comparator for laboratories asking what residues beyond position 29 contribute to affinity and conformation.\u003c\/p\u003e\n\n\u003ch3\u003eIntegrated Mechanistic Profile\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eReceptor engagement:\u003c\/strong\u003e agonism at the growth hormone releasing hormone receptor of the anterior pituitary.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAcyl modification:\u003c\/strong\u003e the trans 3 hexenoyl group confers resistance to peptidase trimming.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFull length scaffold:\u003c\/strong\u003e the complete 44 residue chain distinguishes it from shorter analogues.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e Tesamorelin is supplied strictly for research use only. It is intended as an experimental compound for qualified laboratory personnel and is not a drug, food or cosmetic.\u003c\/p\u003e\n\u003cp\u003eTesamorelin is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Applications (Observations from Studies)\u003c\/h2\u003e\n\u003cp\u003eThe summaries below describe published work involving this molecule. They are not statements about the product offered for sale.\u003c\/p\u003e\n\n\u003ch3\u003eClinical Studies of the Approved Medicine\u003c\/h3\u003e\n\u003cp\u003eThe three references below are human clinical trials of the approved pharmaceutical product, conducted and sponsored by its developer and collaborators. They evaluated a manufactured medicine under regulated conditions. Their findings characterise that medicine and its formulation. They do not characterise research grade material and must not be read as describing the compound sold here.\u003c\/p\u003e\n\n\u003ch3\u003eReceptor and Analytical Characterisation\u003c\/h3\u003e\n\u003cp\u003eSeparately, laboratories use analogues of this class in receptor expressing systems and in analytical method development, where a ligand of known purity supports calibration and evaluation of assay cross reactivity.\u003c\/p\u003e\n\n\u003ch3\u003eComparative Structural Work\u003c\/h3\u003e\n\u003cp\u003eThe full length acylated structure makes this a natural comparator against shorter analogues of the same family, in studies of how chain length and amino terminal modification affect stability.\u003c\/p\u003e\n\n\u003cp\u003eTesamorelin is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eTesamorelin Compared With Related Research Compounds\u003c\/h2\u003e\n\u003cp\u003eThe table below places Tesamorelin alongside two related compounds in the Peptsche range. It is offered to clarify differences in classification, molecular target and research context. It should not be read as a comparison of clinical performance, safety, or suitability for any application.\u003c\/p\u003e\n\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCharacteristic\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eTesamorelin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003ca href=\"\/products\/sermorelin\"\u003eSermorelin\u003c\/a\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003ca href=\"\/products\/cjc-1295\"\u003eCJC-1295\u003c\/a\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eResearch Classification\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSynthetic 44 residue analogue of human growth hormone releasing hormone\u003c\/td\u003e\n\u003ctd\u003eSynthetic 29 residue fragment of human growth hormone releasing hormone\u003c\/td\u003e\n\u003ctd\u003eSynthetic 29 residue analogue of growth hormone releasing factor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Molecular Target\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrowth hormone releasing hormone receptor on pituitary somatotrophs\u003c\/td\u003e\n\u003ctd\u003eGrowth hormone releasing hormone receptor on pituitary somatotrophs\u003c\/td\u003e\n\u003ctd\u003eGrowth hormone releasing factor receptor on pituitary somatotrophs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMechanistic Profile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAgonism at the growth hormone releasing hormone receptor, with an acyl group resisting peptidase trimming\u003c\/td\u003e\n\u003ctd\u003eAgonism at the growth hormone releasing hormone receptor, unmodified parent scaffold\u003c\/td\u003e\n\u003ctd\u003eAgonism at the growth hormone releasing hormone receptor, with a brief plasma profile\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Research Focus\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eComparative structural work, receptor and analytical characterisation\u003c\/td\u003e\n\u003ctd\u003eReference comparator in analogue design, peptide modification chemistry, endocrine signalling models\u003c\/td\u003e\n\u003ctd\u003eReceptor pharmacology, comparative stability and analytical method development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStructural Design\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull 44 residue chain, trans 3 hexenoyl group at the amino terminus, terminal amide\u003c\/td\u003e\n\u003ctd\u003eResidues 1 to 29 with a terminal amide, one methionine, no unnatural residues\u003c\/td\u003e\n\u003ctd\u003e29 residues with four substitutions, no albumin binding moiety\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThe molecule is the active ingredient in an approved medicine marketed as Egrifta by Theratechnologies. Material supplied is research grade, is not that medicine, and is not approved for human or veterinary use\u003c\/td\u003e\n\u003ctd\u003eFormerly the active ingredient in an approved medicine marketed as Geref by EMD Serono, with all products under those applications now discontinued. Material supplied is research grade, is not that former medicine, and is not approved for human or veterinary use\u003c\/td\u003e\n\u003ctd\u003eResearch use compound, not approved for human or veterinary use in any jurisdiction, and withdrawn from consideration on the United States Food and Drug Administration bulk drug substances list\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\u003cp\u003eTesamorelin is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eLaboratory Handling and Storage Considerations\u003c\/h2\u003e\n\u003cp\u003eThis is a large peptide with a hydrophobic amino terminal group, and the lyophilized powder is hygroscopic. Vials should reach ambient temperature before opening so condensation does not form on the cold cake. Sealed vials are stable at 2 to 8 °C when kept dry and dark.\u003c\/p\u003e\n\u003cp\u003eIn solution stability falls sharply and aggregation is a real concern for a molecule of this size carrying an acyl chain. Solutions should be sterile filtered, buffered, refrigerated, protected from light and used within a window the laboratory sets by its own testing. Aliquot into single use portions, and prefer glass or low binding polypropylene labware because adsorption losses are significant.\u003c\/p\u003e\n\n\u003ch3\u003eLaboratory Safety Considerations\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePersonal protective equipment:\u003c\/strong\u003e laboratory coat, nitrile gloves and eye protection whenever the vial is open.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEngineering controls:\u003c\/strong\u003e handle open vials inside a certified fume hood or containment enclosure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExposure prevention:\u003c\/strong\u003e avoid contact with skin and eyes, do not inhale the powder, never pipette by mouth.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e keep sealed at 2 to 8 °C, protected from heat, light and moisture, in a restricted area.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpill response:\u003c\/strong\u003e restrict access, avoid raising dust, collect with a damp wipe, then decontaminate and seal the waste.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDisposal:\u003c\/strong\u003e treat unused material and contaminated consumables as chemical laboratory waste under institutional rules.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDocumentation:\u003c\/strong\u003e record lot number, receipt date, storage conditions and quantities used for traceability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCertificate of Analysis and Quality Assurance\u003c\/h2\u003e\n\u003cp\u003eEvery production lot of Tesamorelin supplied by Peptsche undergoes analytical evaluation, and a batch specific Certificate of Analysis accompanies each order to support research documentation, quality control and experimental consistency.\u003c\/p\u003e\n\u003cp\u003eEach Certificate of Analysis typically includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIdentity verification\u003c\/strong\u003e using analytical techniques such as mass spectrometry to confirm the molecular characteristics of the material supplied.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity analysis\u003c\/strong\u003e performed by high performance liquid chromatography to quantify purity and identify potential impurities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBatch documentation\u003c\/strong\u003e recording lot number, testing date, analytical methods applied and quality assessment results.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTraceability information\u003c\/strong\u003e to support laboratory recordkeeping and reproducibility across research workflows.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePeptsche works with Janoshik Analytical, an independent testing laboratory, for third party verification of research material quality. Independent testing provides transparency and confidence in product identity, consistency and sourcing, and batch specific documentation can be retained as part of laboratory records and internal quality procedures.\u003c\/p\u003e\n\u003cp\u003eTesamorelin is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is Tesamorelin?\u003c\/h3\u003e\n\u003cp\u003eTesamorelin is a synthetic 44 residue analogue of human growth hormone releasing hormone, distinguished from the native peptide by a trans 3 hexenoyl group at the amino terminus. The same molecule is the active ingredient in an approved prescription medicine marketed as Egrifta by Theratechnologies. The material supplied by Peptsche is a research grade compound, is not that approved medicine, is not manufactured to pharmaceutical standards, and is not approved for human or veterinary use.\u003c\/p\u003e\n\u003ch3\u003eWhat is Tesamorelin studied for in research?\u003c\/h3\u003e\n\u003cp\u003eLaboratories use analogues of this class in receptor expressing systems and in analytical method development, where a ligand of known purity supports calibration and evaluation of assay cross reactivity. The full length acylated structure also makes the molecule a comparator against shorter analogues in studies of how chain length and amino terminal modification affect stability. The clinical trials cited on this page evaluated the approved medicine and its formulation and do not characterise research grade material.\u003c\/p\u003e\n\u003ch3\u003eHow does Tesamorelin work in laboratory research?\u003c\/h3\u003e\n\u003cp\u003eTesamorelin binds the growth hormone releasing hormone receptor on anterior pituitary somatotrophs, a class B G protein coupled receptor signalling mainly through the stimulatory G protein. The trans 3 hexenoyl group shields the first residues from aminopeptidase and dipeptidyl peptidase activity, giving a longer usable measurement window in matrices where the unmodified hormone would already have degraded. The complete 44 residue chain adds helical stability and binding surface relative to shorter analogues.\u003c\/p\u003e\n\u003ch3\u003eHow is the quality of Peptsche Tesamorelin verified?\u003c\/h3\u003e\n\u003cp\u003eEvery production lot of Peptsche Tesamorelin is evaluated analytically, with identity confirmed using techniques such as mass spectrometry and purity quantified by high performance liquid chromatography. Peptsche works with Janoshik Analytical, an independent testing laboratory, for third party verification, and a batch specific Certificate of Analysis accompanies each order.\u003c\/p\u003e\n\u003ch3\u003eHow should unopened Tesamorelin be stored?\u003c\/h3\u003e\n\u003cp\u003eUnopened vials should be stored sealed at 2 to 8 °C, protected from heat, light and moisture. Vials should reach ambient temperature before opening so condensation does not form on the cold powder. Lot number, receipt date and storage conditions should be recorded in laboratory documentation so results stay traceable to a batch.\u003c\/p\u003e\n\u003ch3\u003eIs Tesamorelin intended for human use?\u003c\/h3\u003e\n\u003cp\u003eNo. Tesamorelin is supplied strictly for laboratory research use only. It is not approved for human consumption, veterinary use, diagnosis, treatment or any medical application.\u003c\/p\u003e\n\u003ch3\u003eWhy do researchers choose Peptsche for Tesamorelin?\u003c\/h3\u003e\n\u003cp\u003ePeptsche supplies Tesamorelin at 99% or greater purity by HPLC, verified per batch, as a lyophilized powder in a vial sealed with a butyl closure and crimp. Each lot is released against batch specific analytical documentation, and independent third party confirmatory analysis supports reproducibility across research workflows.\u003c\/p\u003e\n\n\u003ch2\u003eScientific References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eFalutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359 to 2370. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18057338\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/18057338\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eFalutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. Journal of Clinical Endocrinology and Metabolism. 2010;95(9):4291 to 4304. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20554713\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/20554713\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eStanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases. 2012;54(11):1642 to 1651. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22495074\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/22495074\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2\u003eRESEARCH USE ONLY\u003c\/h2\u003e\n\u003cp\u003eThese compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.\u003c\/p\u003e","brand":"Peptsche","offers":[{"title":"10mg","offer_id":43752788656191,"sku":"PEP-TESA-10MG","price":65.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/7394\/0287\/files\/peptsche_Tesamorelin_10mg.png?v=1786904254","url":"https:\/\/peptsche.com\/products\/tesamorelin","provider":"Peptsche","version":"1.0","type":"link"}